Cocrystal Pharma Inc (OTCBB:COCP) share price has been advancing on above average volume and the share price has increased 7.25% as of close on March 11. This small cap company boasts quite a market valuation but volume is far from what it used to be. COCP is attempting to woo investors at upcoming investor conferences.

COCP plans to attend two such events in March. The first investor conference will take place on March 14th at the Ritz Carlton in California and the second will take place in Miami Florida at Loews Beach Hotel.

Investors and shareholders are excited about the recent development when COCP announced in-licensing of a technology for hepatitis B virus and human papilloma. It signed an agreement with two prominent universities; Duke University and Emory University. COCP is licensing multiple patents relating to the possible development of a cure for Hep B and human papilloma virus. If COCP is able to deliver on this promise, it will be a huge advancmenet not only in terms of profitability for the company but also for bettering society and the world. There is an estimated 2 billion people worldwide that have Hep B. In addition, the papilloma virus continues to be one of the most common STD.

The license agreement established between the two universities allow COCP to develop and likely commercialize a cure for Hep B and the Papilloma Virus. In order to do so, COCP wil have to utilize the underlying patents and technologies developed by Duke and Emory Universities.

Management at COCP is a powerhouse which should be a confidence booster to investors and shareholders. The veteran team consists of industry leaders of whom some have even won Nobel Peace Prize. A huge booster should be billionaire investor Phillip Frost who has a keen eye for picking microcap biotech companies and growing them which is how he developed his fortune. Phillip Frost currently one of the members of the board of directors.

We have a Monster Pick Coming. Subscribe Right Now!

Cocrystal Pharma Inc (OTCBB:COCP)

COCP is currently trading at a $447 million market valuation. Given the recent advancements that the company is making to increase investor awareness and the recent development of licensing technology and patents from two prominent universities to develop a cure for two large markets should provide COCP with a boost in confidence. Phillip Frost is a powerhouse in the Biotech industry and should not be taken lightly. Stay tuned for more developments.

We will be updating on COCP when more details emerge so make sure you are subscribed to Microcapspot so you know what’s going on with COCP .

Disclosure: we hold no position in COCP either long or short and we have not been compensated for this article.

SHARE

NO COMMENTS

LEAVE A REPLY